Indero Showcasing Dermatology Expertise at EADV Congress in Paris

Indero is proud to highlight the contributions of its team at the 2025 EADV Congress in Paris, one of the leading global events in dermatology research and innovation.

Late-Breaking Presentation

On September 18th, Dr. Robert Bissonnette, Founder and Executive Chairman of Indero, presented a late-breaking session titled: “Safety of Delgocitinib Cream in Adult Patients with Chronic Hand Eczema (CHE): Pooled Analysis of Five Phase 2b and Phase 3 Trials.”

This presentation was part of a LEO Pharma late phase program, in which Indero’s clinical research unit, Innovaderm Research, served as an active site.

ePoster Contributions

POSTER ID P4065 | Sarah Vahey, Diane Potvin, and Pina D’Angelo also co-authored an ePoster titled: “Which primary endpoint should I choose for an AD study to best discern a difference from placebo?”

In addition to his presentations, Dr. Bissonnette contributed to several ePosters! Learn more here.

These engagements underscore Indero’s commitment to advancing dermatological science and improving the lives of patients affected by skin diseases.

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.

INNOVADERM CRO IS NOW INDERO.

Translation